Interventions of Interest inotersen (Tegsedi®, Akcea Therapeutics) patisiran (Onpattro®, Alnylam Pharmaceuticals) ICER reviewed new therapies for the treatment of hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council voted unanimously that, despite the net health benefit, both inotersen and […]
2017 Interventions of Interest: TNF Inhibitors Adalimumab (Humira®, Abbvie) Certolizumab pegol (Cimzia®, UCB) Etanercept (Enbrel®, Amgen) Golimumab (Simponi®, Janssen) Infliximab (Remicade®, Janssen) CD20- Directed Cytolytic Antibody Rituximab (Rituxan®, Genentech) T Cell Inhibitor Abatacept (Orencia®, BMS) IL-6 Inhibitors Sarilumab (Kevzara®, Sanofi and Regeneron Pharmaceuticals) Tocilizumab (Actemra®, Genentech) JAK- Inhibitors Tofacitinib (Xeljanz®, Pfizer) Baricitinib (Olumiant®, Eli Lilly […]
Interventions of Interest: JAK- Inhibitors Baricitinib (Olumiant®, Eli Lilly and Co.) Tofacitinib (Xeljanz®, Pfizer) Upadacitinib (Rinvoq™, AbbVie) adalimumab (Humira®, AbbVie) Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages […]
Intervention of interest: Mepolizumab (Nucala®, GlaxoSmithKline plc.) An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health and limit the ability to pursue many activities. For questions, contact […]
Interventions of Interest Dupilumab (Dupixent®, Sanofi/Regeneron) Omalizumab (Xolair®, Genentech/Novartis) Mepolizumab (Nucala®, GlaxoSmithKline) Reslizumab (Cinqair®, Teva) Benralizumab (Fasenra™, AstraZeneca) An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health […]
Interventions of Interest: crisaborole (Eucrisa®, Pfizer, Inc.) dupilumab (Dupixent®, Sanofi and Regeneron, Inc.) Atopic dermatitis (eczema) is a chronic/chronically-relapsing skin condition characterized by itching and dry skin. Atopic dermatitis is common. It affects 5-20% of children worldwide, and approximately 11% of children in the US. It is also estimated to affect around 3-7% of adults […]
Interventions of interest: Antiarrhythmic drugs (amiodarone, dronedarone) Catheter ablation Surgical ablation Atrial fibrillation (AF) is the most common cardiac arrhythmia in the US population. AF occurs when rapid, disorganized electrical signals cause the atria (the two upper chambers of the heart) to “fibrillate”, or contract quickly and irregularly. This in turn causes some blood to […]
Interventions of interest: Parent behavior training School-based interventions Stimulants Non-stimulants Diagnoses of Attention Deficit Hyperactivity Disorder (ADHD) have risen in recent years, and ADHD is now regarded to be a common condition among children in the United States. While reported prevalence ranges widely between 6-16% depending on location and measurement technique, it has been estimated […]
Intervention of interest: Programs to integrate behavioral health into the primary care setting Providers in the US health care system often assess and treat patients with physical health conditions and behavioral health conditions (e.g., mental health and substance use disorders) in siloes, yet physical and behavioral health are inextricably linked. Up to 70% of physician […]
Intervention of Interest LentiGlobin (Zynteglo®, Bluebird Bio) ICER planned to assess the comparative clinical effectiveness and value of LentiGlobin (Bluebird Bio) for the treatment of beta thalassemia. LentiGlobin is an investigational gene therapy currently marketed in Europe under the brand name Zynteglo®. On December 5, 2019, ICER launched our assessment of LentiGlobin, originally intending to conclude the […]